Skip to main content
Extrawell Pharmaceutical Holdings Limited logo

Extrawell Pharmaceutical Holdings Limited — Investor Relations & Filings

Ticker · 858 HKEX Manufacturing
Open in API
Filings indexed 795 across all filing types
Latest filing 2026-04-14 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 858

About Extrawell Pharmaceutical Holdings Limited

http://www.extrawell.com.hk

Extrawell Pharmaceutical Holdings Limited functions as an investment holding entity specializing in the pharmaceutical industry. Its core business activities are segmented into Manufacturing and Trading. The Manufacturing segment encompasses the development, production, and sale of proprietary pharmaceutical products. The Trading segment is dedicated to the promotion, marketing, and distribution of imported specialized pharmaceuticals, alongside healthcare and nutritional products. Operations and sales are primarily concentrated within the People's Republic of China market.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Share Issue/Capital Change Classification · 1% confidence The document is a Next Day Disclosure Return (Form FF305) filed under the Hong Kong Stock Exchange listing rules, detailing changes in issued shares (new share issuance via conversion of convertible bonds) and confirming compliance. It is not an earnings release, annual report, or proxy statement. It concerns a change in capital structure via new share issues. Therefore it falls under Share Issue/Capital Change (SHA).
2026-04-14 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2026
Regulatory Filings Classification · 1% confidence The document is the HKEX Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” under Chapter 19B of the Listing Rules, detailing share capital, issued shares, public float confirmation, options, convertibles, etc. It is neither an earnings release, annual or interim report, nor a proxy or AGM material, but a routine regulatory submission. No specific category exists for monthly returns in the provided list, so it falls under the fallback category of general Regulatory Filings (RNS).
2026-04-02 English
MEMORANDUM OF UNDERSTANDING IN RELATION TO THE POSSIBLE SALE OF THE CONVERTIBLE BONDS
Capital/Financing Update Classification · 1% confidence The document is a voluntary announcement by Extrawell Pharmaceutical regarding a non-legally binding memorandum of understanding to potentially sell its convertible bonds and/or assign its interest in an amendment deed. It concerns a potential transaction affecting the company's capital structure and financing (sale of convertible debt), rather than management changes, dividends, or a proxy statement. This falls under updates on financing activities and capital structure changes, matching the Capital/Financing Update category (CAP).
2026-03-27 English
COMPLETION OF DISCLOSEABLE TRANSACTION AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO A SHARE BUY-BACK TRANSACTION OF A NON-WHOLLY OWNED SUBSIDIARY
Regulatory Filings Classification · 1% confidence The document is an announcement regarding the completion of a share buy-back transaction by a subsidiary of Extrawell Pharmaceutical Holdings Limited. It details the fulfillment of conditions, the reduction of share capital, and the resulting change in equity interest. While it involves a transaction, it does not fit the specific 'Transaction in Own Shares' (POS) category, which is typically reserved for the company's own share buybacks. It is a corporate announcement regarding a disclosable and connected transaction, which falls under the general regulatory filing category for corporate actions.
2026-03-17 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2026
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. Since it is a recurring regulatory filing regarding share capital and securities movements that does not fit into specific categories like 'Share Issue' (which is for specific events) or 'Transaction in Own Shares' (which is for buybacks), it is best classified as a general Regulatory Filing.
2026-03-02 English
(1) EXTENSION OF LONG STOP DATE IN RESPECT OF PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS (2) DELAY IN DESPATCH OF CIRCULAR IN RESPECT OF THE MAJOR TRANSACTION IN RELATION TO T
Regulatory Filings Classification · 1% confidence The document is an announcement from Extrawell Pharmaceutical Holdings Limited regarding the extension of a long stop date for bond amendments and a delay in the dispatch of a circular related to a major transaction. This document describes specific corporate actions regarding financing and transaction timelines rather than being a full report or a simple publication notice. It falls under the category of M&A Activity (TAR) as it pertains to a 'major transaction' and the associated regulatory process for bond amendments.
2026-02-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.